Contra-indicated in patients with active pathological bleeding.
- TRADE NAME: Savaysa (Daiichi Sankyo)
- INDICATIONS: Reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis and pulmonary embolism
- CLASS: Direct factor Xa inhibitor
- HALF-LIFE: 10–14 hours
- FDA APPROVAL DATE: 01/08/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anticoagulants, Rifampin
- See adverse reactions attributed to class:
REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CRCL>95ml/min, ISCHEMIC EVENTS ON PREMATURE DISCONTINUATION and SPINAL/EPIDURAL HEMATOMA
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of edoxaban in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 10/26/2024
